InMed Pharmaceuticals (NASDAQ: INM) Receives Three U.S. Patents Strengthening Its Patent Portfolio
InMed Pharmaceuticals (NASDAQ: INM) has received three U.S. patents, further strengthening its patent portfolio. This news showcases the company's commitment to developing new drug treatments and protecting their innovations.
This news highlights InMed Pharmaceuticals' commitment to developing new drug treatments and protecting their innovations, impacting the pharmaceutical industry and potential future medical breakthroughs.